Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Solid Biosciences Inc.

SLDB · Nasdaq · CIK 0001707502 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

2 Form 4 transaction lines observed in the same window
0 sales · 2 option, withholding, award, gift or other lines

Last qualifying purchase2025-03-11 · Kahn Clare · $9.9K

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesNone
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
SMITH IAN FDirector
○○
● Purchase▼ Sale○ Other

—

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-03-11 · Kahn Clare.

Recent Form 4 activity

0Purchases
29Sales
33Other Form 4 lines
34SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER2 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
12,726,346
Previous report
17,106,152
Avg daily volume
1,655,956
Days to cover
7.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2025-03-11Kahn ClarePurchase (P)Common Stock1,860USD 5.34USD 9,932SEC filing ↗
2025-02-19EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Xontogeny Venture Fund, LPPurchase (P)Common Stock5,000,000USD 4.03USD 20,150,000SEC filing ↗
2025-02-19BCIP Life Sciences Associates, LP; BCLS II Equity Opportunities GP, LLC; BCLS II Equity Opportunities, LP; BCLS II Investco (GP), LLC; BCLS II Investco, LP; BCLS SB Investco, LP; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC; Bain Capital Life Sciences Partners, LPPurchase (P)Common Stock1,000,000USD 4.03USD 4,030,000SEC filing ↗
2025-02-18Adage Capital Management, L.P.; Atchinson Robert; Gross PhillipPurchase (P)Common Stock, $0.001 par value per share252,545USD 7.56USD 1,909,240SEC filing ↗
2024-06-07Kahn ClarePurchase (P)Common Stock1,100USD 7.67USD 8,437SEC filing ↗
2024-01-11Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; Shah Rajeev M.Purchase (P)Common Stock904,160USD 5.53USD 5,000,005SEC filing ↗
2024-01-11EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTD; Perceptive Xontogeny Venture Fund, LPPurchase (P)Common Stock3,410,713USD 5.53USD 18,861,243SEC filing ↗
2021-03-23EDELMAN JOSEPH; PERCEPTIVE ADVISORS LLC; PERCEPTIVE LIFE SCIENCES MASTER FUND LTDPurchase (P)Common Stock2,608,695USD 5.75USD 14,999,996SEC filing ↗
2021-03-19Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.Purchase (P)Common Stock2,206,685USD 5.75USD 12,688,439SEC filing ↗

Form 4 evidence

62 transaction lines in the latest 365-day window; 207 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02SMITH IAN FOption exercise / conversion (M)Common Stock3,440USD —USD —SEC filing ↗
2026-07-02SMITH IAN FOption exercise / conversion (M)Common Stock3,440USD —USD —SEC filing ↗
2026-04-02SMITH IAN FOption exercise / conversion (M)Common Stock3,441USD —USD —SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-02SMITH IAN FOption exercise / conversion (M)Common Stock3,440USD —USD —SEC filing ↗
2026-07-02SMITH IAN FOption exercise / conversion (M)Common Stock3,440USD —USD —SEC filing ↗
2026-04-02SMITH IAN FOption exercise / conversion (M)Common Stock3,441USD —USD —SEC filing ↗
2026-02-18Tan KevinSale (S)Common Stock5,404USD 5.82USD 31,451SEC filing ↗
2026-02-18Howton David TSale (S)Common Stock7,469USD 5.82USD 43,470SEC filing ↗
2026-02-18Herzich PaulSale (S)Common Stock3,616USD 5.82USD 21,045SEC filing ↗
2026-02-18Hanrahan JessieSale (S)Common Stock4,134USD 5.82USD 24,060SEC filing ↗
2026-02-18Ganot IlanSale (S)Common Stock2,658USD 5.82USD 15,470SEC filing ↗
2026-02-18Cumbo AlexanderSale (S)Common Stock16,644USD 5.82USD 96,868SEC filing ↗
2026-02-18Brooks GabrielSale (S)Common Stock—USD —USD —SEC filing ↗
2026-02-13Tan KevinOption exercise / conversion (M)Common Stock10,625USD —USD —SEC filing ↗
2026-02-13Howton David TOption exercise / conversion (M)Common Stock14,687USD —USD —SEC filing ↗
2026-02-13Herzich PaulOption exercise / conversion (M)Common Stock7,187USD —USD —SEC filing ↗
2026-02-13Hanrahan JessieOption exercise / conversion (M)Common Stock8,125USD —USD —SEC filing ↗
2026-02-13Ganot IlanOption exercise / conversion (M)Common Stock4,861USD —USD —SEC filing ↗
2026-02-13Cumbo AlexanderOption exercise / conversion (M)Common Stock30,031USD —USD —SEC filing ↗
2026-02-13Brooks GabrielOption exercise / conversion (M)Common Stock10,937USD —USD —SEC filing ↗
2026-02-04Tan KevinSale (S)Common Stock14,783USD 6.44USD 95,203SEC filing ↗
2026-02-04Howton David TSale (S)Common Stock18,894USD 6.44USD 121,677SEC filing ↗
2026-02-04Herzich PaulSale (S)Common Stock10,905USD 6.44USD 70,228SEC filing ↗
2026-02-04Hanrahan JessieSale (S)Common Stock12,348USD 6.44USD 79,521SEC filing ↗
2026-02-04Ganot IlanSale (S)Common Stock7,205USD 6.44USD 46,400SEC filing ↗
2026-02-04Cumbo AlexanderSale (S)Common Stock48,913USD 6.44USD 315,000SEC filing ↗
2026-02-04Brooks GabrielSale (S)Common Stock12,616USD 6.44USD 81,247SEC filing ↗
2026-02-02Tan KevinSale (S)Common Stock26,837USD 6.44USD 172,830SEC filing ↗
2026-02-02Howton David TSale (S)Common Stock37,771USD 6.44USD 243,245SEC filing ↗
2026-02-02Herzich PaulSale (S)Common Stock26,250USD 6.44USD 169,050SEC filing ↗
2026-02-02Hanrahan JessieSale (S)Common Stock26,535USD 6.44USD 170,885SEC filing ↗
2026-02-02Cumbo AlexanderSale (S)Common Stock80,258USD 6.44USD 516,862SEC filing ↗
2026-02-02Brooks GabrielSale (S)Common Stock28,335USD 6.44USD 182,477SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerSLDB
CIK0001707502
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
ExchangeNasdaq

Data coverage

Local Form 4 history207 transaction lines from 2020-02-10 to 2026-10-02
9 P purchase lines · 76 S sale lines · 122 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.